No Data
No Data
Lyra Therapeutics Announces It Will Present 52-Week Extension Stage Results For ENLIGHTEN 1 Phase 3 Study For LYR-210 For The Treatment of Chronic Rhinosinusitis At COSM May 14-18 2025 In New Orleans
Lyra Therapeutics GAAP EPS of -$0.13 Beats by $0.01, Revenue of $0.18M Beats by $0.02M
Lyra Therapeutics | 10-Q: Quarterly report
Lyra Therapeutics | 8-K: Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Press Release: Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics 1Q Loss $8.55M >LYRA
loading...